Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology - Basic: Therapy, Metrics and Intervention

First experience in proteasome inhibitor therapy of dedifferentiated, radioiodine negative, somatostatin-receptor negative thyroid cancer

Daniel Putzer, Michael Gabriel, Wolfgang Eisterer, Dorota Kendler, Rupert Prommegger, Ruth Madleitner, Georg Dobrozemsky, Guenther Gastl and Irene Virgolini
Journal of Nuclear Medicine May 2009, 50 (supplement 2) 1667;
Daniel Putzer
1Innsbruck Medical University, Department of Nuclear Medicine, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Gabriel
1Innsbruck Medical University, Department of Nuclear Medicine, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang Eisterer
2Innsbruck Medical University, Department of Internal Medicine, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dorota Kendler
1Innsbruck Medical University, Department of Nuclear Medicine, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rupert Prommegger
3Innsbruck Medical University, Department of Surgery, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth Madleitner
1Innsbruck Medical University, Department of Nuclear Medicine, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georg Dobrozemsky
1Innsbruck Medical University, Department of Nuclear Medicine, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guenther Gastl
2Innsbruck Medical University, Department of Internal Medicine, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irene Virgolini
1Innsbruck Medical University, Department of Nuclear Medicine, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 50 no. supplement 2 1667

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online November 3, 2014.

Copyright & Usage 
© 2009 by Society of Nuclear Medicine

Author Information

  1. Daniel Putzer1,
  2. Michael Gabriel1,
  3. Wolfgang Eisterer2,
  4. Dorota Kendler1,
  5. Rupert Prommegger3,
  6. Ruth Madleitner1,
  7. Georg Dobrozemsky1,
  8. Guenther Gastl2 and
  9. Irene Virgolini1
  1. 1Innsbruck Medical University, Department of Nuclear Medicine, Innsbruck, Austria
  2. 2Innsbruck Medical University, Department of Internal Medicine, Innsbruck, Austria
  3. 3Innsbruck Medical University, Department of Surgery, Innsbruck, Austria

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: November 2014 to April 2025

AbstractFullPdf
Nov 20141200
Mar 2015100
Jul 2015100
Sep 2015500
Feb 2016800
Sep 2016100
Nov 2016100
Jan 2017300
Mar 2017100
May 2017100
Jun 2017300
Sep 2017100
Dec 2017100
Jan 2018100
Feb 2018100
Mar 2018100
Sep 2018500
Oct 2018100
Mar 2019100
May 2020100
Oct 2020100
Dec 2020500
Jan 2021100
Feb 2021700
Mar 20212500
Apr 20213100
May 20211100
Jun 2021300
Jul 2021500
Aug 2021300
Sep 2021300
Oct 2021200
Nov 2021300
Dec 2021200
Jan 20221100
Feb 2022200
Mar 2022300
Apr 2022300
May 2022400
Jun 2022200
Jul 2022600
Aug 2022100
Sep 2022100
Oct 2022100
Dec 2022300
Feb 2023100
Mar 2023300
Apr 2023100
May 2023200
Jun 2023200
Jul 2023100
Aug 2023300
Sep 2023200
Oct 2023300
Nov 2023100
Dec 2023200
Jan 2024300
Feb 2024300
Mar 2024300
Apr 2024300
May 2024100
Jun 2024400
Aug 20241300
Sep 20241100
Oct 2024200
Nov 2024500
Dec 2024300
Jan 2025200
Mar 2025100
Apr 2025600
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 50, Issue supplement 2
May 2009
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
First experience in proteasome inhibitor therapy of dedifferentiated, radioiodine negative, somatostatin-receptor negative thyroid cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
First experience in proteasome inhibitor therapy of dedifferentiated, radioiodine negative, somatostatin-receptor negative thyroid cancer
Daniel Putzer, Michael Gabriel, Wolfgang Eisterer, Dorota Kendler, Rupert Prommegger, Ruth Madleitner, Georg Dobrozemsky, Guenther Gastl, Irene Virgolini
Journal of Nuclear Medicine May 2009, 50 (supplement 2) 1667;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
First experience in proteasome inhibitor therapy of dedifferentiated, radioiodine negative, somatostatin-receptor negative thyroid cancer
Daniel Putzer, Michael Gabriel, Wolfgang Eisterer, Dorota Kendler, Rupert Prommegger, Ruth Madleitner, Georg Dobrozemsky, Guenther Gastl, Irene Virgolini
Journal of Nuclear Medicine May 2009, 50 (supplement 2) 1667;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology - Basic: Therapy, Metrics and Intervention

  • Radioimmunotherapy (RIT) with anti-CD45 antibody: Optimal timing of the preload
  • Preliminary study of a biodegradable seed: 32P-chromic phosphate-poly (L-lactide) on its biodegradation, pharmacokinetics of 32P nanoparticles after intratumor implantation
  • SUV analysis underestimates antitumor activity of a new drug
Show more Oncology - Basic: Therapy, Metrics and Intervention

Therapy Metrics and Intervention Posters

  • Radioimmunotherapy (RIT) with anti-CD45 antibody: Optimal timing of the preload
  • Preliminary study of a biodegradable seed: 32P-chromic phosphate-poly (L-lactide) on its biodegradation, pharmacokinetics of 32P nanoparticles after intratumor implantation
  • SUV analysis underestimates antitumor activity of a new drug
Show more Therapy Metrics and Intervention Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire